FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Interiors and More IPO and Zenith Drugs IPO.
Interiors and More IPO is a SME Book Built Issue IPO proposed to list at NSE SME while Zenith Drugs IPO is a SME Book Built Issue proposed to list at NSE SME.
Interiors and More IPO | Zenith Drugs IPO | |
---|---|---|
Logo | ||
Issue Category | SME | SME |
Issue Type | IPO | IPO |
Process Type | Book Built Issue | Book Built Issue |
Listing At | NSE SME | NSE SME |
Lead Managers | Gretex Corporate Services Limited | Gretex Corporate Services Limited |
Registrar | Bigshare Services Pvt Ltd | Bigshare Services Pvt Ltd |
Market Maker | Gretex Share Broking Private Limited | Gretex Share Broking Private Limited |
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | Anchor Investor | Anchor Investor |
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Interiors and More IPO is up to ₹42.00 Cr whereas the issue size of the Zenith Drugs IPO is up to ₹40.68 Cr. The final issue price of Interiors and More IPO is ₹227.00 per share and of Zenith Drugs IPO is ₹79.00 per share.
Interiors and More IPO | Zenith Drugs IPO | |
---|---|---|
Face Value | ₹10 per share | ₹10 per share |
Issue Price (Lower) | ₹216.00 per share | ₹75.00 per share |
Issue Price (Upper) | ₹227.00 per share | ₹79.00 per share |
Issue Price (Final) | ₹227.00 per share | ₹79.00 per share |
Discount (Retail) | ||
Discount (Employee) | ||
Market Lot Size | 600 shares | 1600 shares |
Fresh Issue Size | 18,50,400 shares | 51,48,800 shares |
Fresh Issue Size (Amount) | up to ₹42.00 Cr | up to ₹40.68 Cr |
OFS Issue Size | ||
OFS Issue Size (Amount) | ||
Issue Size Total | 18,50,400 shares | 51,48,800 shares |
Issue Size Total (Amount) | up to ₹42.00 Cr | up to ₹40.68 Cr |
Interiors and More IPO opens on Feb 15, 2024, while Zenith Drugs IPO opens on Feb 19, 2024. The closing date of Interiors and More IPO and Zenith Drugs IPO is Feb 20, 2024, and Feb 22, 2024, respectively.
Interiors and More IPO | Zenith Drugs IPO | |
---|---|---|
Anchor Bid Date | Feb 14, 2024 | Feb 16, 2024 |
Issue Open | Feb 15, 2024 | Feb 19, 2024 |
Issue Close | Feb 20, 2024 | Feb 22, 2024 |
Basis Of Allotment (Tentative) | Feb 21, 2024 | Feb 23, 2024 |
Initiation of Refunds (Tentative) | Feb 22, 2024 | Feb 26, 2024 |
Credit of Share (Tentative) | Feb 22, 2024 | Feb 26, 2024 |
Listing date (Tentative) | Feb 23, 2024 | Feb 27, 2024 |
Anchor Lockin End date 1 | Mar 22, 2024 | Mar 24, 2024 |
Anchor Lockin End date 2 | May 21, 2024 | May 23, 2024 |
Interiors and More IPO P/E ratio is 19.7, as compared to Zenith Drugs IPO P/E ratio of 18.4.
Interiors and More IPO | Zenith Drugs IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial | Interiors and More Limited Financial Information (Restated)Interiors and More Limited's revenue increased by 153.09% and profit after tax (PAT) rose by 467.64% between the financial year ending with March 31, 2023 and March 31, 2022.
|
Zenith Drugs Limited Financial Information (Restated Consolidated)Zenith Drugs Limited's revenue increased by 24.85% and profit after tax (PAT) rose by 64.7% between the financial year ending with March 31, 2023 and March 31, 2022.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 95.08% | 100.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 69.93% | 69.98% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | 19.7 | 18.4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ₹158.80 Cr. | ₹135.48 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROE | 84.68%% | 35.13%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROCE | 75.58%% | 37.29%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | 1.45 | 1.51 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPS | ₹11.52 | ₹4.29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RoNW | 59.57%% | 29.88%% |
In the Interiors and More IPO retail investors (RII) are offered 6,15,600 shares while in Zenith Drugs IPO retail investors are offered 6,15,600 shares. Qualified institutional buyers (QIB) are offered 3,51,600 shares in Interiors and More IPO and 8,59,200 shares in Zenith Drugs IPO.
Interiors and More IPO | Zenith Drugs IPO | |
---|---|---|
Anchor Investor Reserveration | 5,26,200 shares | 12,88,000 shares |
Market Maker Reserveration | 93,000 shares | 8,52,800 shares |
QIB | 3,51,600 shares | 8,59,200 shares |
NII | 2,64,000 shares | 6,44,800 shares |
RII | 6,15,600 shares | 15,04,000 shares |
Employee | 0 shares | 0 shares |
Others | ||
Total | 12,31,200 shares | 30,08,000 shares |
Interiors and More IPO subscribed 11.22x in total, whereas Zenith Drugs IPO subscribed 179.18x.
Interiors and More IPO | Zenith Drugs IPO | |
---|---|---|
QIB (times) | 3.54x | 106.72x |
NII (times) | 30.32x | 368.77x |
Big NII (times) | ||
Small NII (times) | ||
RII (times) | 7.41x | 139.28x |
Employee (times) | ||
Other (times) | ||
Total (times) | 11.22x | 179.18x |
Add a public comment...
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|